These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 14556007

  • 1. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG, McDonald ER, Herman JG, El-Deiry WS.
    Nat Genet; 2003 Nov; 35(3):229-37. PubMed ID: 14556007
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 3. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
    Qi H, Gervais ML, Li W, DeCaprio JA, Challis JR, Ohh M.
    Mol Cancer Res; 2004 Jan 04; 2(1):43-52. PubMed ID: 14757845
    [Abstract] [Full Text] [Related]

  • 4. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Jan 04; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 5. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 7. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.
    Nature; 1999 May 20; 399(6733):271-5. PubMed ID: 10353251
    [Abstract] [Full Text] [Related]

  • 8. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S, Desrosiers RR, Beliveau R.
    Am J Physiol Renal Physiol; 2004 Feb 20; 286(2):F338-48. PubMed ID: 14583436
    [Abstract] [Full Text] [Related]

  • 9. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

  • 10. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.
    IUBMB Life; 2001 Jul 30; 52(1-2):43-7. PubMed ID: 11795592
    [Abstract] [Full Text] [Related]

  • 11. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ.
    Mol Cell Biol; 2002 Mar 30; 22(6):1947-60. PubMed ID: 11865071
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.
    Cancer Res; 2004 Dec 01; 64(23):8595-603. PubMed ID: 15574766
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K, Makino Y, Pereira T, Poellinger L.
    EMBO J; 2000 Aug 15; 19(16):4298-309. PubMed ID: 10944113
    [Abstract] [Full Text] [Related]

  • 14. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T.
    Oncol Rep; 2005 Jun 15; 13(6):1033-41. PubMed ID: 15870918
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.
    Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, Minato N, Ohno S, Shuin T.
    J Biol Chem; 2001 Nov 23; 276(47):43611-7. PubMed ID: 11574546
    [Abstract] [Full Text] [Related]

  • 19. The von Hippel-Lindau tumor suppressor gene.
    Kondo K, Kaelin WG.
    Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ.
    Cell Cycle; 2012 Dec 01; 11(23):4462-73. PubMed ID: 23159849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.